We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current IVA market cap is 154M. The company's latest EPS is EUR -2.1189 and P/E is -1.39.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 11.36M | 8.17M | 8.83M | 18.82M | 23.16M |
| Operating Income | -29.97M | -27.49M | -51.94M | -57.11M | -104.7M |
| Net Income | -30.22M | -33.62M | -49.64M | -54.27M | -110.43M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 56.96M | 138.92M | 121.99M | 116M | 69.56M |
| Total Liabilities | 15.57M | 27.71M | 33.12M | 70.53M | 101.59M |
| Total Equity | 41.39M | 111.21M | 88.87M | 45.48M | -32.03M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -28.4M | -30.59M | -47.63M | -44.93M | -81.61M |
| Investing | -826k | -8.56M | -1.79M | 8.87M | -7.73M |
| Financing | 8.38M | 111.68M | 25.45M | 37.27M | 29.08M |
| Market Cap | 154M |
| Price to Earnings Ratio | -1.39 |
| Price to Sales Ratio | 6.64 |
| Price to Cash Ratio | 5.71 |
| Price to Book Ratio | -4.8 |
| Dividend Yield | - |
| Shares Outstanding | 52.12M |
| Average Volume (1 week) | 19.08k |
| Average Volume (1 Month) | 28.53k |
| 52 Week Change | 32.81% |
| 52 Week High | 4.84 |
| 52 Week Low | 2.125 |
| Spread (Intraday) | 0.02 (0.51%) |
| Company Name | Inventiva |
| Address |
50 rue de dijon daix 21121 |
| Website | https://www.inventivapharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
